(122 days)
The UV Active Implant System is indicated for surgical placement in the upper and lower jaw arches, to provide a root form means for single or multiple units' prosthetic attachment to restore a patient's chewing function.
The narrow (Ø3.0, Ø3.3) implant is limited to the replacement of maxillary lateral incisors and mandibular incisors. It is intended for delayed loading.
The Regular (Ø3.8 ~ Ø5.5) implants can be placed with a conventional two stage surgical process with an option for transmucosal healing or they can be placed in a single stage surgical process for immediate loading when good primary stability is achieved with appropriate occlusal loading.
The Wide (Ø5.9 ~ Ø6.4) implants can be placed with a conventional two stage surgical process with an option for transmucosal healing and are indicated for the molar region with delayed loading.
The UV Active Implant System includes UV Active Fixture, Abutments (Multi- unit abutment, Cemented abutment, Angled abutment, Solid abutment and Mill abutment), Cylinders (Temporary cylinder, Cemented cylinder, CCM Cylinder) and screws (Abutment screw, Cylinder screw). The UV Active Implant System is specially designed for using in dental implant surgery. A successfully osseointegrated fixtures will achieve a firm implant when the fixture is operated under the controlled conditions per well-known clinical studies. There are intended for use in partially or fully edentulous mandibles and maxillae, in support of single or multiple-unit restorations.
The UV Active Fixture is made of pure titanium grade 4(ASTM F67) and surface treatment is done with SLA (Sand-blasted, Large grit, Acid-atched). The fixtures have the diameter (3.06.4mm) and length (7.013.0mm).
The multi-unit abutment have the diameter of 4.8mm and the angle has straight, 20° and 30°. It is made from titanium alloy conforming to ASTM F136.
The Cemented abutment, Angled abutment, Solid abutment and Mill abutment has same diameter when comparing to each primary predicate device. The subject device and the predicate device are the same except for surface treatment change from machined surface to TiN Coated surface. The Cemented abutment, Solid abutment and Mill abutment made from titanium alloy confirming to ASTM F67. The Abutment screw and Cylinder screw are made of titanium alloy confirming to ASTM F136 and no surface treatment for these components.
The Fixtures are supplied gamma sterilization. The abutments, screws and cylinders are provided nonsterile, these should be user steam sterilized before use.
The provided text describes a 510(k) submission for the UV Active Implant System, which is an endosseous dental implant system. The document focuses on demonstrating substantial equivalence to predicate devices rather than providing a detailed study design for acceptance criteria based on performance metrics such as sensitivity, specificity, and AUC. The "acceptance criteria" discussed are related to meeting standards for medical devices and demonstrating substantial equivalence.
Based on the provided information, I can extract the following:
1. Table of Acceptance Criteria and Reported Device Performance
The acceptance criteria are not in the format of sensitivity/specificity/AUC, but rather conformance to established medical device standards and demonstrated substantial equivalence to predicate devices.
| Acceptance Criteria Category | Specific Acceptance Criteria (Standards Met) | Device Performance/Outcome |
|---|---|---|
| Sterilization Validation | ISO 11137-1, 11137-2, 11137-3 (Gamma) | Achieved SAL of 10^-6 |
| ISO 17665-2 (Steam) | All testing requirements met | |
| Shelf Life Testing | ASTM F1980 (Accelerated aging) | Accelerated aging results supported; real-time testing ongoing |
| ASTM F88 (Seal peeling) | Met | |
| ASTM F1140 (Burst test) | Met | |
| ASTM F1929 (Dye penetration) | Met | |
| ASTM F2096 (Bubble test) | Met | |
| Sterility test | Met | |
| Appearance | Met | |
| Dimension Test | Met | |
| Fatigue Test | ISO 14801:2007 | Met criteria ("worst case scenario chosen") |
| Biocompatibility | ISO 10993-1 (Biological evaluation) | No new issues of biocompatibility raised |
| ISO 10993-5 (Cytotoxicity in vitro) | Met | |
| ISO 10993-12 (Sample preparation) | Met | |
| Substantial Equivalence | Comparison to predicate devices (K122519, K173975, K170608, K161987, K062129, K071357, K150199, K161416, K141457, K161689) across various characteristics (materials, design, dimensions, indications for use, surface treatment, etc.) | Found to be substantially equivalent. Differences in packaging were validated not to affect safety/efficiency. Differences in diameter and Indications For Use are mitigated by reference predicate devices. |
2. Sample Size Used for the Test Set and Data Provenance
The document does not describe a "test set" in the context of a clinical performance study with human subjects, nor does it refer to data provenance in terms of country of origin or retrospective/prospective collection for an AI/CAD-like device. The testing described is non-clinical testing on the device itself (e.g., sterilization, fatigue, biocompatibility). Therefore, there is no mention of sample size for human subjects or data provenance.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and the Qualifications of those Experts
Not applicable. This device is not an AI/CAD system evaluated by experts for ground truth establishment.
4. Adjudication Method for the Test Set
Not applicable.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
Not applicable. No AI/CAD functionality is described in this submission.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
Not applicable. No AI/CAD functionality is described in this submission.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)
The "ground truth" in this context is the fulfillment of established engineering, material, and biological standards through laboratory testing. For example:
- Sterilization: Measured sterility assurance level (SAL).
- Fatigue: Measured force resistance and cycles to failure against ISO 14801:2007.
- Biocompatibility: In vitro cytotoxicity assays and general biological evaluation against ISO 10993 series.
- Dimensional/Material: Conformance to specified dimensions and material properties (e.g., CP Ti Gr4 (ASTM F67), Ti-6Al-4V ELI (ASTM F136)).
8. The Sample size for the Training Set
Not applicable. There is no training set mentioned, as this is not an AI/CAD device.
9. How the ground truth for the training set was established
Not applicable.
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo features the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.
December 14, 2018
DIO Corporation % Peter Kang Business, Manager DIO USA 3470 Wilshire Blvd, #620 Los Angeles, California 90010
Re: K182194
Trade/Device Name: UV Active Implant System Regulation Number: 21 CFR 872.3640 Regulation Name: Endosseous Dental Implant Regulatory Class: Class II Product Code: DZE, NHA Dated: November 22, 2018 Received: November 29, 2018
Dear Peter Kang:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{1}------------------------------------------------
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.htm); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Andrew I. Steen -S
for Tina Kiang, Ph.D. Acting Director Division of Anesthesiology. General Hospital, Respiratory, Infection Control, and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number (if known) K182194
Device Name UV Active Implant System
Indications for Use (Describe)
The UV Active Implant System is indicated for surgical placement in the upper and lower jaw arches, to provide a root form means for single or multiple units' prosthetic attachment to restore a patient's chewing function.
The narrow (Ø3.0, Ø3.3) implant is limited to the replacement of maxillary lateral incisors and mandibular incisors. It is intended for delayed loading.
The Regular (03.8 ~ Ø5.5) implants can be placed with a conventional two stage surgical process with an option for transmucosal healing or they can be placed in a single stage surgical process for immediate loading when good primary stability is achieved with appropriate occlusal loading.
The Wide (06.0 ~ Ø6.4) implants can be placed with a conventional two stage surgical process with an option for transmucosal healing and are indicated for the molar region with delayed loading.
X Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
Image /page/3/Picture/1 description: The image shows the logo for DIO Implant Solution. The logo consists of the letters "DIO" in a bold, sans-serif font. The "DI" is in gray, while the "O" is in pink and has a small pink circle above it, resembling a dot over the letter "i". Below the letters, in a smaller font, are the words "Implant Solution".
510(k) Summary
K182194
This 510(k) Summary is being submitted in accordance with requirement of 21 CFR part 807.92
Submitter:
Jiae Park DIO Corporation 66 Centum seo-ro, Haeundae-gu, Busan, Republic of Korea Phone +82-51-745-7836 Fax +82-51-745-7781
Contact / US agent:
Peter Kang DIO USA. 3470 Wilshire Blvd. #620 Los Angeles, CA Phone +1-213-365-2875 +1-213-365-1595 Fax
Device Information:
Trade Name: UV Active Implant System Common Name: Endosseous dental implant Fixture Classification Name: Fixture, Implant, Dental, Endosseous Device Class: Class II Product Code: DZE Secondary product code : NHA Panel: Dental Regulation Number: 21 CFR 872.3640 Date prepared: 12/11/2018
General Description
The UV Active Implant System includes UV Active Fixture, Abutments (Multi- unit abutment, Cemented abutment, Angled abutment, Solid abutment and Mill abutment), Cylinders (Temporary cylinder, Cemented cylinder, CCM Cylinder) and screws (Abutment screw, Cylinder screw). The UV Active Implant System is specially designed for using in dental implant surgery. A successfully osseointegrated fixtures will achieve a firm implant when the fixture is operated under the controlled conditions per well-known clinical studies. There are intended for use in partially or fully edentulous mandibles and maxillae, in support of single or multiple-unit restorations.
The UV Active Fixture is made of pure titanium grade 4(ASTM F67) and surface treatment is done with SLA (Sand-blasted, Large grit, Acid-atched). The fixtures have the diameter (3.06.4mm) and length (7.013.0mm).
The multi-unit abutment have the diameter of 4.8mm and the angle has straight, 20° and 30°. It is made from titanium alloy conforming to ASTM F136.
The Cemented abutment, Angled abutment, Solid abutment and Mill abutment has same diameter when comparing to each primary predicate device. The subject device and the predicate device are the same except for surface treatment change from machined surface to TiN Coated surface. The Cemented abutment, Solid abutment and Mill abutment made from titanium alloy confirming to ASTM F67. The Abutment screw and Cylinder screw are made of titanium alloy confirming to ASTM F136 and no surface treatment for these components.
The Fixtures are supplied gamma sterilization. The abutments, screws and cylinders are provided nonsterile, these should be user steam sterilized before use.
Page 1 of 156
{4}------------------------------------------------
Image /page/4/Picture/1 description: The image shows the logo for DIO Implant Solution. The logo consists of the letters "DIO" with "DI" in gray and "O" in pink. Above the "O" is a small pink circle. Below the letters is the text "Implant Solution" in gray.
Indication For Use
The UV Active Implant System is indicated for surgical placement in the upper and lower jaw arches, to provide a root form means for single or multiple units' prosthetic attachment to restore a patient's chewing function.
The narrow (Ø3.0, Ø3.3) implant is limited to the replacement of maxillary lateral incisors and mandibular incisors. It is intended for delayed loading.
The Regular (Ø3.8 ~ Ø5.5) implants can be placed with a conventional two stage surgical process with an option for transmucosal healing or they can be placed in a single stage surgical process for immediate loading when good primary stability is achieved with appropriate occlusal loading.
The Wide (05.9 ~ Ø6.4) implants can be placed with a conventional two stage surgical process with an option for transmucosal healing and are indicated for the molar region with delayed loading.
Predicate and Reference Devices
The subject device is substantially equivalent to the following Predicate and Reference Device:
Primary Predicate Device :
DIO UF HSA Internal Sub-merged Implant System(K122519)
Reference Devices :
UF(II) Wide Fixture (K173975) UF(II) Implant System (K170608) UF(II) NarrowImplant System- Fixture,UF(II) NarrowImplant System- Superstructure(K161987) P.004 Implants (K062129) P.004 NC Anatomic abutment(K071357) Neodent Implant System CM Anatomic Abutment(K150199) Nobel Biocare AB(K161416) Dentium Implantium® and SuperLine® Abutment (K141457) OSSTEM Implant System-Abutment (K161689)
{5}------------------------------------------------
Image /page/5/Picture/1 description: The image shows the logo for DIO Implant Solution. The logo consists of the letters "DIO" in a bold, gray sans-serif font. To the right of the letters, there is a pink circle with a smaller pink circle above and to the right of it, resembling a stylized "O". Below the letters, the words "Implant Solution" are written in a smaller, gray sans-serif font.
Summaries of Technological Characteristics
The subject device is substantially equivalent to they are substantially equivalent in intended use, material and comection interfaces to the implants are identical for each individual diameter and connection type. Comparison demonstrating Substantial Equivalence follows:
1) UV Active Fixture
| Subject Device | Primary Predicate Device | Reference Device | |||
|---|---|---|---|---|---|
| Applicant | DIO Corporation | DIO Corporation | DIO Corporation | DIO Corporation | DIO Corporation |
| Trade Name | UV Active Implant System | DIO UF HSA Internal Sub-Merged Implant System | UF(II) Wide Fixture | UF(II) Implant System | UF(II) Narrow ImplantSystem |
| 510(K) No. | Not yet assigned | K122519 | K173975 | K170608 | K161987 |
| ClassificationName | Endosseous Dental Implant,Fixture(872.3640) | Endosseous Dental Implant,Fixture(872.3640) | Endosseous DentalImplant, Fixture(872.3640) | Endosseous Dental Implant,Fixture(872.3640) | Endosseous Dental Implant,Fixture(872.3640) |
| Product Code | DZE | DZE | DZE | DZE | DZE |
| Class | II | II | II | II | II |
| Material | CP Ti Gr4(ASTM F67) | CP Ti Gr4(ASTM F67) | CP Ti Gr4(ASTM F67) | CP Ti Gr4(ASTM F67) | CP Ti Gr4(ASTM F67) |
| Design | Internal Type and MorseTapered | Internal Type and MorseTapered | Internal Type and MorseTapered | Internal Type and MorseTapered | Internal Type and MorseTapered |
| FixtureDiameter(mm) | 3.0~6.4 | 3.8~7.0 | 5.9~6.9 | 3.8~5.5 | 3.0, 3.3 |
Page 3 of 14
<DIO-QP-402-07_Rev.02>
{6}------------------------------------------------
DIO Corporation Traditional 510(k) Submission
Image /page/6/Picture/1 description: The image shows the logo for DIO Implant Solution. The logo consists of the letters "DIO" in a bold, sans-serif font. The "DI" is in gray, while the "O" is in pink with a small pink circle above and to the right of it. Below the letters, the words "Implant Solution" are written in a smaller, sans-serif font.
| Implant SolutionUV Active Implant System | |||||
|---|---|---|---|---|---|
| FixtureLength(mm) | Ø3.0 – L 8.5, 10, 11.5, 13Ø3.3 – L 8.5, 10, 11.5, 13Ø3.8 – L 8.5, 10, 11.5, 13Ø4.0 – L 8.5, 10, 11.5, 13Ø4.5 – L 7, 8.5, 10, 11.5, 13Ø5.0 – L 7, 8.5, 10, 11.5, 13Ø5.5 – L 7, 8.5, 10, 11.5, 13Ø5.9 – L 7, 8.5, 10, 11.5, 13Ø6.4 – L 7, 8.5, 10, 11.5, 13 | Ø3.8 – L 7.0, 8.5, 10, 11.5, 13, 15, 16Ø4.0 – L 7.0, 8.5, 10, 11.5, 13, 15, 16, 18Ø4.5 – L 7.0, 8.5, 10, 11.5, 13, 15, 16, 18Ø5.0 – L 7.0, 8.5, 10, 11.5, 13, 15, 16, 18Ø5.5 – L 7, 8.5, 10, 11.5, 13, 15, 16, 18Ø6.0 – L 7, 8.5, 10.5, 12.5, 14.5Ø6.4 – L 7, 8.5, 10.5, 12.5, 14.5Ø7.0 – L 7, 8.5, 10.5, 12.5, 14.5 | Ø5.9 – L 7, 8.5, 10, 11.5, 13Ø6.4 – L 7, 8.5, 10, 11.5, 13Ø6.9 – L 7, 8.5, 10, 11.5, 13 | Ø3.8 – L 8.5, 10, 11.5, 13, 15, 16Ø4.0 – L 8.5, 10, 11.5, 13, 15, 16Ø4.5 – L 7.0, 8.5, 10, 11.5, 13, 15, 16Ø5.0 – L 7.0, 8.5, 10, 11.5, 13, 15, 16Ø5.5 – L 7, 8.5, 10, 11.5, 13, 15, 16 | Ø3.0 – L 8.5, 10, 11.5, 13, 15Ø3.3 – L 8.5, 10, 11.5, 13, 15 |
| FixtureSurface | SLA | SLA | SLA | SLA | SLA |
| Treatment | |||||
| Sterile | Gamma Sterilization | Gamma Sterilization | Gamma Sterilization | Gamma Sterilization | Gamma Sterilization |
| Indications ForUse | The UV Active ImplantSystem is indicated forsurgical placement in theupper and lower jawarches, to provide a rootform means for single ormultiple units' prostheticattachment to restore apatient's chewingfunction.The narrow (Ø3.0, Ø3.3)implant is limited to thereplacement of maxillarylateral incisors andmandibular incisors. It isintended for delayedloading.The Regular (Ø3.8 ~Ø5.5) implants can beplaced with aconventional two stagesurgical process withan option fortransmucosal healing orthey can be placed in asingle stage surgicalprocess for immediateloading when goodprimary stability isachieved withappropriate occlusal | The DIO UF HSA InternalSub-Merged ImplantSystem is indicated forsurgical placement in theupper and lower jaw arches,to provide a root formmeans for single or multipleunits' prosthetic attachmentto restore a patient'schewing function. Thesmaller (Ø3.8 ~ Ø5.5)implants can be placed witha conventional two stagesurgical process with anoption for transmucosalhealing or they can beplaced in a single stagesurgical process forimmediate loading whengood primary stability isachieved with appropriateocclusal loading. The larger(Ø6.0 ~ Ø7.0) implants canbe placed with aconventional two stagesurgical process with anoption for transmucosalhealing and are indicated forthe molar region withdelayed loading. | The UF(II) Wide Fixtureis indicated for surgicalplacement in the upperand lower jaw arches, toprovide a root formmeans for single ormultiple units' prostheticattachment to restore apatient's chewingfunction. The larger (Ø5.9 ~ Ø6.9mm)implants can be placedwith a conventional twostage surgical processwith an option fortransmucosal healing andare indicated for themolar region withdelayed loading. | The UF(II) Implant Systemis indicated for surgicalplacement in the upper andlower jaw arches, to providea root form means for singleor multiple units' prostheticattachment to restore apatient's chewingfunction. The UF(II)ImplantSystem(Ø 3.8 ~ Ø 5.5) canbe placed with aconventional two stagesurgical process with anoption for transmucosalhealing or they can beplaced in a single stagesurgical process forimmediate loading whengood primary stability isachieved with appropriateocclusal loading. | The UF(II) Narrow ImplantSystem is intended for two-stage surgical procedures inthe following situations andwith the following clinicalprotocols:-The intended use for the3.0mm, 3.3mm diameterUF(II) Narrow Implant islimited to the replacementofmaxillary lateral incisorsand mandibular incisors.-Immediate placement inextraction sites and insituations with a partially orcompletely healed alveolarridge.- It is intended for delayedloading. |
| loading.The Wide ( ${\O}$ 5.9 ~ ${\O}$ 6.4)implants can be placed witha conventional two stagesurgical process with anoption for transmucosalhealing and are indicatedfor the molar region withdelayed loading. | |||||
| SubstantialEquivalenceComparison | UV Active Fixture is substantially equivalent in designs, dimensions, material and technological characteristics with the identified primary predicatedevice except for packaging changes, diameter and slightly different in Indications for use. The UV Active Fixture is same in fundamental scientifictechnology to the predicate device in that they all have been designed, manufactured and tested in compliance with FDA's Class II specialcontrols guidance document root-food endosseous dental implants and endosseous dental implant abutments. | ||||
| The Packaging of the subject device is different from the predicate devices. However, this difference is mitigated by the validation of the packaging forsubject device, verifying that the packaging differences do not affect the safety and efficiency of the device. | |||||
| The diameter difference between Subject device and Primary predicate device occurred because the subject device has Narrow size fixture( ${\O}$ 3.0, ${\O}$ 3.3). It is mitigated by Reference predicate device (K161987). | |||||
| The Indication for use is differences between the Subject device and Primary predicate device (K122519). Different of Indication for useoccurred because the subject device has Narrow size fixture ( ${\O}$ 3.0, ${\O}$ 3.3). The difference of Indication for use is mitigated by Referencepredicate device (K161987). The diameter length of 6.9mm is not part of this submission and all of the subject device dimension are includedpredicate device diameter range. Thus, the proposed indications do not increase risk nor change the intended use of the device and are found tobe substantially equivalent. | |||||
| Any differences in technology characteristics are accompanied by information that demonstrated the device is substantially equivalent as thepredicate and do not raise different questions of safety and effectiveness than the predicate |
Page 4 of 14
<DIO-QP-402-07_Rev.02>
{7}------------------------------------------------
DIO Corporation Traditional 510(k) Submission UV Active Implant System
Image /page/7/Picture/1 description: The image shows the logo for DIO Implant Solution. The logo consists of the letters "DIO" in a bold, sans-serif font. The "DI" is in gray, while the "O" is in pink with a small pink circle above and to the right of it. Below the letters, in a smaller font, is the text "Implant Solution".
Page 5 of 14
<DIO-QP-402-07_Rev.02>
{8}------------------------------------------------
Image /page/8/Picture/1 description: The image shows the logo for DIO Implant Solution. The logo consists of the letters "DIO" in a bold, sans-serif font, with the "D" and "I" in gray and the "O" in pink. Below the letters, the words "Implant Solution" are written in a smaller, sans-serif font, also in gray.
Page 6 of 14
<DIO-QP-402-07_Rev.02>
{9}------------------------------------------------
Image /page/9/Picture/1 description: The image shows the logo for DIO Implant Solution. The logo consists of the letters "DIO" in a bold, sans-serif font. The "DI" is in gray, while the "O" is in pink and has a small pink circle above it. Below the letters, the words "Implant Solution" are written in a smaller, sans-serif font.
-
- Multi-unit Abutment
| Subject Device | Reference Device | ||||
|---|---|---|---|---|---|
| Applicant | DIO Corporation | Nobel Biocare AB | Dentium | DIO Corporation | |
| Trade Name | UV Active Implant System | Multi-unit Abutment Plus | Dentium Implantium® andSuperLine® Abutment | UF(II) Narrow ImplantSystem | |
| 510(K) No. | Not yet assigned | K161416 | K141457 | K161987 | |
| Material | Ti-6Al-4V ELI (ASTM F136) | Titanium vanadium alloy | Pure Ti-G4(ASTM F67) | Ti-6Al-4V ELI(ASTM F136) | |
| Design | Straight Multi-unit abutmentImage: Straight Multi-unit abutment | Angled Multi-unit abutmentImage: Angled Multi-unit abutment | Image: Multi-unit Abutment Plus | Image: Dentium Implantium and SuperLine Abutment | Image: UF(II) Narrow Implant System |
| AbutmentDiameters(mm) | 4.8 | 4.8 | 4.5~5.5 | 4.0 | |
| Cuffheight(mm) | 1.5/2.5/3.5/4.5/5.5 | 1.5/2.5/3.5/4.5 | 1.0~1.5 | 2.5/3.0/4.0/5.0 | |
| Angle(°) | 0/20/30 | 0/17/30 | 15~30 | 20 |
Page 7 of 14
<DIO-QP-402-07_Rev.02>
{10}------------------------------------------------
Image /page/10/Picture/1 description: The image shows the logo for DIO Implant Solution. The logo consists of the letters "DIO" in a bold, sans-serif font, with "DI" in gray and "O" in pink. Below the letters, the words "Implant Solution" are written in a smaller, sans-serif font, also in gray.
2) Abutment Screw
| Subject Device | Primary Predicated Device | Reference Device | |
|---|---|---|---|
| Applicant | DIO Corporation | DIO Corporation | OSSTEM Implant Co., Ltd. |
| Trade Name | UV Active Implant System | DIO UF HSA INTERNAL SUB-MERGEDIMPLANT SYSTEM | OSSTEM Implant System -Abutment |
| 510(K) No. | Not yet assigned | K122519 | K161689 |
| Material | Ti-6Al-4V ELI (ASTM F136) | Ti-6Al-4V ELI (ASTM F136) | Ti-6Al-4V ELI |
| Design | Image: Subject Device Design | Image: Primary Predicated Device Design | Image: Reference Device Design |
| Diameters( $Ø$ ) | 2.2 | 1.8/2.0 | 2.0/2.05/2.2/2.3/2.5 |
| Lengths (mm) | 6.0 | 8.5/11.5 | 3.35/5.6/7.5/8.35/9.6/10.2 |
Page 8 of 14
<DIO-QP-402-07_Rev.02>
{11}------------------------------------------------
Image /page/11/Picture/1 description: The image shows the logo for DIO Implant Solution. The letters "DIO" are displayed in a bold, sans-serif font, with "DI" in gray and "O" in pink with a small pink circle above it. Below the letters, the words "Implant Solution" are written in a smaller, sans-serif font.
| Subject Device | Reference Device | Reference Device | ||||
|---|---|---|---|---|---|---|
| Applicant | DIO Corporation | DIO Corporation | DIO Corporation | |||
| Trade Name | UV Active Implant System | UF(II) Narrow Implant System | UF(II) Implant System | |||
| 510(K) No. | Not yet assigned | K161987 | K170608 | |||
| Material | Titanium Grade 4(ASTM F67) | Titanium Grade 4(ASTM F67) | Titanium Grade 4(ASTM F67) | |||
| Hex | Non-Hex | Hex | Non-Hex | Hex | Non-Hex | |
| Design | Image: Hex design of subject device | Image: Non-Hex design of subject device | Image: Hex design of reference device | Image: Non-Hex design of reference device | Image: Hex design of reference device | Image: Non-Hex design of reference device |
| Diameters (mm) | 4.0/4.5 | 4.0/4.5 | 4.5/5.5/6.5/7.5 | |||
| Lengths (mm) | 4.0/5.5/7.0 | 4.0/5.5/7.0 | 4.0/5.5/7.0 | |||
| Surface Treatment | TiN Coated | Machined Type | TiN Coated |
3) Cemented Abutment
Page 9 of 14
<DIO-QP-402-07_Rev.02>
{12}------------------------------------------------
Image /page/12/Picture/1 description: The image shows the logo for DIO Implant Solution. The logo consists of the letters "DIO" with "DI" in gray and "O" in pink. Below the letters, the words "Implant Solution" are written in gray.
4) Angled abutment
| Angled abutment | |||
|---|---|---|---|
| Subject Device | Primary Predicate Device | Reference device | |
| Applicant | DIO Corporation | DIO Corporation | DIO Corporation |
| Trade Name | UV Active Implant System | DIO UF HSA INTERNALSUB- MERGED IMPLANT | UF(II) Narrow Implant System |
| 510(K) No. | Not yet assigned | K122519 | K161987 |
| Material | Ti-6Al-4V ELI (ASTM F136) | Ti-6Al-4V ELI (ASTM F136) | Ti-6Al-4V ELI (ASTM F136) |
| Design | Image: Subject Device Design | Image: Primary Predicate Device Design | Image: Reference Device Design |
| AbutmentDiameters (mm) | 4.0/4.5/5.5 | 4.5/5.5 | 4.0 |
| Angle (°) | Ø4.0 - 15Ø4.5 - 15, 25Ø5.5 - 15, 25 | Ø4.5 – 15, 25Ø5.5 - 15, 25 | Ø4.0 - 15 |
| SurfaceTreatment | TiN Coated | Machined Type | Machined Type |
Page 10 of 14
<DIO-QP-402-07_Rev.02>
{13}------------------------------------------------
Image /page/13/Picture/1 description: The image shows the logo for DIO Implant Solution. The logo consists of the letters "DIO" in a bold, sans-serif font, with "DI" in gray and "O" in pink. Above the "O" is a small pink circle. Below the logo is the text "Implant Solution" in a smaller, sans-serif font.
| Subject Device | Primary Predicate Device | Reference Device | |
|---|---|---|---|
| Applicant | DIO Corporation | DIO Corporation | DIO Corporation |
| Trade Name | UV Active Implant System | UF(II) Narrow Implant System | UF(II) Implant Ssytem |
| 510(K) No. | Not yet assigned | K161987 | K170608 |
| Material | Titanium Grade4(ASTM F67) | Titanium Grade4(ASTM F67) | Titanium Grade4(ASTM F67) |
| Design | Image: Subject Device Design | Image: Primary Predicate Device Design | Image: Reference Device Design |
| AbutmentDiameters (mm) | 4.0/4.5 | 4.0/4.5 | 4.5/5.5/6.5/7.5 |
| AbutmentLength(mm) | 4.0/5.5/7.0 | 4.0/5.5/7.0 | 4.0/5.5/7.0 |
| SurfaceTreatment | TiN Coated | Machined Type | TiN Coated |
5) Solid abutment
Page 11 of 14
<DIO-QP-402-07_Rev.02>
{14}------------------------------------------------
Image /page/14/Picture/1 description: The image shows the logo for DIO Implant Solution. The logo consists of the letters "DIO" in a bold, sans-serif font, with "DI" in gray and the "O" in pink. Above the pink "O" is a smaller pink circle. Below the letters is the text "Implant Solution" in a smaller, sans-serif font.
| 6) Ball abutment | |||
|---|---|---|---|
| Subject Device | Primary Predicate Device | Reference Device | |
| Applicant | DIO Corporation | DIO Corporation | DIO Corporation |
| Trade Name | UV Active Implant System | DIO UF HSA INTERNAL SUB- MERGEDIMPLANT SYSTEM | UF(II) Narrow Implant System |
| 510(K) No. | Not yet assigned | K122519 | K161987 |
| ClassificationName | Endosseous Dental Implant, Abutment(872.3630) | Endosseous Dental Implant, Abutment(872.3630) | Endosseous Dental Implant, Abutment(872.3630) |
| Product Code | NHA | NHA | NHA |
| Class | II | II | II |
| Material | Ti-6Al-4V ELI (ASTM F136) | ASTM F67 (Ti CP-4) | Ti-6Al-4V ELI (ASTM F136) |
| Design | Image: Ball abutment | Image: Ball abutment | Image: Ball abutment |
| AbutmentDiameters (mm) | 3.5 | 3.5 | 3.5 |
| AbutmentLength(mm) | 1.0/2.0/3.0/4.0/5.0/6.0/7.0 | 1.0/2.0/3.0/4.0/5.0/6.0 | 1.0/2.0/3.0/4.0/5.0/6.0/7.0 |
| SurfaceTreatment | TiN Coated | Machined Type | Machined Type |
Page 12 of 14
<DIO-QP-402-07_Rev.02>
{15}------------------------------------------------
Image /page/15/Picture/1 description: The image shows the logo for DIO Implant Solution. The logo consists of the letters "DIO" in gray, with the "O" stylized as a pink circle with a smaller pink circle inside. Below the letters, the words "Implant Solution" are written in a smaller, gray font.
| 7) Mill abutment | ||
|---|---|---|
| Subject Device | PrimaryPredicate Device | |
| Applicant | DIO Corporation | DIO Corporation |
| Trade Name | UV Active Implant System | DIO UF HSA INTERNAL SUB-MERGED IMPLANTSYSTEM |
| 510(K) No. | Not yet assigned | K122519 |
| Material | Titanium Grade4(ASTM F67) | Titanium Grade4(ASTM F67) |
| Design | Image: Two yellow cylinders | Image: A gray cylinder |
| AbutmentDiameters (mm) | 4.0/4.5/5.5/6.5/7.5 | 4.0/4.5/5.5/6.5/7.5 |
| AbutmentLength(mm) | 17.0/17.6/17.8/18.4/19.6/20.4 | 17.0/17.8 |
| SurfaceTreatment | TiN Coated | Machined Type |
Page 13 of 14
<DIO-QP-402-07_Rev.02>
{16}------------------------------------------------
Image /page/16/Picture/1 description: The image shows the logo for DIO Implant Solution. The logo consists of the letters "DIO" in a bold, gray font, with the "O" being a pink circle with a smaller pink circle above and to the right. Below the letters, in a smaller gray font, are the words "Implant Solution."
Non-clinical Testing
The results of the non-clinical testing demonstrate that the results have met the criteria of the standards, and the subject device is substantially equivalent to the predicate device. This testing included:
Sterilization Validation and Shelf Life Testing
Sterilization validating testing has been performed in accordance with ISO 11137-1, ISO 11137-2, ISO 11137-3, ISO 11737-1, and ISO 11737-2 for gamma sterilization and ISO 17665-2 for steam sterilization. Test results have demonstrated that the SAL of 10-6 was achieved and all testing requirements were met. For the subject devices provided sterile, accelerated aging shelf life testing was conducted according to ASTM F1980; real time testing is being conducted to support accelerated aging results.
- Seal peeling test according to ASTM F88
- Burst test according to ASTM F1140
- Dye penetration test according to ASTM F1929
- Bubble test according to ASTM F2096
- Sterility test
- Appearance
- Dimension Test
Fatigue Test
The fatigue test was performed on the subject device in accordance with ISO 14801:2007 Dentistry-Implants-Dynamic fatigue test for Endosseous Dental Implants. The worst case scenario was chosen based on the FDA guidance "Class II Special Controls Guidance Document: Root-form Endosseous Dental Implants and Endosseous Dental Implant Abutments".
The subject device was tested to evaluate its substantial equivalence according to the following standards. - Fatigue Test according to ISO 14801:2007
Biocompatibility
Biocompatibility was evaluated with accordance to ISO 10993-1 for Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process, considering exhaustive extractions and potential biological (cytotoxic) reaction.
The following test performed on the subject device.
- Cytotoxicity per ISO 10993-5
The cytotoxicity test was conducted using selected worst-case products with accordance to above mentioned ISO 10993-1 as well as; ISO 10993-5 for Biological evaluation of medical devices - Part 5: Tests for in vitro cytotoxicity. and;
ISO 10993-12 for Biological evaluation of medical devices -- Part 12: Sample preparation and reference materials.
No new issues of biocompatibility are raised for the subject devices.
Conclusions
The UV Active Implant System constitutes a substantially equivalent medical device, meeting all the declared requirements of its intended use. This system has the same intended use and fundamental scientific technology as its predicate device. Therefore, UV Active Implant System sand its predicates are substantially equivalent.
§ 872.3640 Endosseous dental implant.
(a)
Identification. An endosseous dental implant is a prescription device made of a material such as titanium or titanium alloy that is intended to be surgically placed in the bone of the upper or lower jaw arches to provide support for prosthetic devices, such as artificial teeth, in order to restore a patient's chewing function.(b)
Classification. (1) Class II (special controls). The device is classified as class II if it is a root-form endosseous dental implant. The root-form endosseous dental implant is characterized by four geometrically distinct types: Basket, screw, solid cylinder, and hollow cylinder. The guidance document entitled “Class II Special Controls Guidance Document: Root-Form Endosseous Dental Implants and Endosseous Dental Implant Abutments” will serve as the special control. (See § 872.1(e) for the availability of this guidance document.)(2)
Classification. Class II (special controls). The device is classified as class II if it is a blade-form endosseous dental implant. The special controls for this device are:(i) The design characteristics of the device must ensure that the geometry and material composition are consistent with the intended use;
(ii) Mechanical performance (fatigue) testing under simulated physiological conditions to demonstrate maximum load (endurance limit) when the device is subjected to compressive and shear loads;
(iii) Corrosion testing under simulated physiological conditions to demonstrate corrosion potential of each metal or alloy, couple potential for an assembled dissimilar metal implant system, and corrosion rate for an assembled dissimilar metal implant system;
(iv) The device must be demonstrated to be biocompatible;
(v) Sterility testing must demonstrate the sterility of the device;
(vi) Performance testing to evaluate the compatibility of the device in a magnetic resonance (MR) environment;
(vii) Labeling must include a clear description of the technological features, how the device should be used in patients, detailed surgical protocol and restoration procedures, relevant precautions and warnings based on the clinical use of the device, and qualifications and training requirements for device users including technicians and clinicians;
(viii) Patient labeling must contain a description of how the device works, how the device is placed, how the patient needs to care for the implant, possible adverse events and how to report any complications; and
(ix) Documented clinical experience must demonstrate safe and effective use and capture any adverse events observed during clinical use.